Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial entities : Beigene, ltd. save search
BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)
Published: 2023-10-17 (Crawled : 21:00) - biospace.com/
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: -2.74%
H: 2.94%
C: 1.41%
lung cancer cell trial response plus
Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers
Published: 2023-06-02 (Crawled : 23:00) - prnewswire.com
ZYME | $8.56 -1.72% -1.75% 340K
|
Health Technology
| Email alert
Add to watchlist
BEIGF | $14.29 -9.87% 2.1K
|
n/a
| Email alert
Add to watchlist
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
| Email alert
Add to watchlist
JAZZ | $109.685 0.79% 0.78% 380K
|
Health Technology
| Email alert
Add to watchlist
asco positive pharmaceuticals trial
AMGEN TO PRESENT NEW REPATHA® (EVOLOCUMAB) AND OLPASIRAN DATA AT ACC
Published: 2023-03-01 (Crawled : 16:00) - biospace.com/
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 4.08%
H: 3.06%
C: 0.89%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.56%
H: 2.63%
C: 2.53%
repatha
Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma
Published: 2023-01-19 (Crawled : 13:00) - biospace.com/
ZYME | $8.56 -1.72% -1.75% 340K
|
Health Technology
|
| O: 4.32%
H: 3.53%
C: -7.21%
JAZZ | $109.685 0.79% 0.78% 380K
|
Health Technology
|
| O: 1.86%
H: 0.0%
C: -1.04%
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 2.58%
H: 1.53%
C: 0.98%
pharmaceuticals trial her2- her2
Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab
Published: 2022-12-19 (Crawled : 13:00) - biospace.com/
ZYME | $8.56 -1.72% -1.75% 340K
|
Health Technology
|
| O: 27.86%
H: 1.69%
C: -17.8%
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: -1.95%
H: 0.99%
C: 0.04%
btc-01 topline trial positive
BLINCYTO® (BLINATUMOMAB) ADDED TO CONSOLIDATION CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN ADULT PATIENTS WITH MEASURABLE RESIDUAL DISEASE-NEGATIVE B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
Published: 2022-12-13 (Crawled : 01:00) - biospace.com/
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 2.79%
H: 1.42%
C: -0.92%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 1.9%
H: 0.23%
C: -3.46%
blincyto leukemia
Leap Therapeutics Announces First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients
Published: 2022-10-17 (Crawled : 12:00) - biospace.com/
LPTX | $3.24 0.94% 0.93% 89K
|
Health Technology
|
| O: -1.14%
H: 4.6%
C: 3.24%
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 4.91%
H: 6.28%
C: 2.04%
dkn-01 treatment therapeutics leap cancer study
LUMAKRAS®/LUMYKRAS® (SOTORASIB) DEMONSTRATES SUPERIOR PROGRESSION-FREE SURVIVAL OVER DOCETAXEL IN FIRST POSITIVE PHASE 3 TRIAL OF A KRAS G12C INHIBITOR IN NON-SMALL CELL LUNG CANCER
Published: 2022-09-11 (Crawled : 00:00) - prnewswire.com
MS | News 0 d | $93.76 1.81% 0.12% 6.4M
|
Finance
|
| O: 0.6%
H: 1.16%
C: 0.17%
CCXI | News | $51.99 -0.04%
|
Health Technology
|
| O: -0.16%
H: 0.16%
C: 0.06%
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: -1.88%
H: 3.78%
C: 3.73%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -3.91%
H: 1.55%
C: -0.16%
lumakras lung trial positive cancer
AMGEN ANNOUNCES TOPLINE DATA FROM LUMAKRAS® (SOTORASIB) PHASE 3 TRIAL IN NON-SMALL CELL LUNG CANCER
Published: 2022-08-30 (Crawled : 21:00) - prnewswire.com
CCXI | News | $51.99 -0.04%
|
Health Technology
|
| O: 0.12%
H: 0.16%
C: -0.31%
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 3.3%
H: 1.98%
C: 0.39%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 1.03%
H: 0.95%
C: -0.53%
lumakras lung topline trial cancer
AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 959, BIOSIMILAR CANDIDATE TO SOLIRIS® (ECULIZUMAB)
Published: 2022-08-23 (Crawled : 14:00) - biospace.com/
CCXI | News | $51.99 -0.04%
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: -0.57%
H: 1.88%
C: 0.59%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.09%
H: 0.0%
C: -0.9%
soliris candidate biosimilar positive results study
Leap Therapeutics Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer
Published: 2022-07-12 (Crawled : 21:00) - biospace.com/
LPTX | $3.24 0.94% 0.93% 89K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -8.8%
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: -0.58%
H: 4.0%
C: 1.51%
dkn-01 trials therapeutics leap cancer
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 2 DATA FOR INVESTIGATIONAL OLPASIRAN IN ADULTS WITH ELEVATED LIPOPROTEIN(a)
Published: 2022-05-31 (Crawled : 17:00) - biospace.com/
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 4.16%
H: 3.44%
C: -1.66%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.1%
H: 0.89%
C: 0.68%
topline positive phase 2
AMGEN ANNOUNCES RESULTS FROM TWO OPEN LABEL EXTENSION STUDIES OF REPATHA® (EVOLOCUMAB)
Published: 2022-04-27 (Crawled : 14:00) - biospace.com/
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 1.64%
H: 6.35%
C: 1.76%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.33%
H: 1.2%
C: -0.1%
repatha label results
AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 654, BIOSIMILAR CANDIDATE TO STELARA® (USTEKINUMAB)
Published: 2022-04-18 (Crawled : 22:00) - biospace.com/
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: -1.9%
H: 0.12%
C: -3.78%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.46%
H: 0.0%
C: 0.0%
stelara biosimilar positive results phase 3 topline
IRC Determines BRUKINSA® (Zanubrutinib) Demonstrates Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia
Published: 2022-04-11 (Crawled : 11:00) - biospace.com/
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: -2.56%
H: 0.15%
C: -3.72%
brukinsa leukemia trial response
LUMAKRAS® (SOTORASIB) SHOWS ENCOURAGING AND CLINICALLY MEANINGFUL ANTICANCER ACTIVITY IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED PANCREATIC CANCER IN CODEBREAK 100 TRIAL
Published: 2022-02-14 (Crawled : 23:00) - prnewswire.com
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 4.23%
H: 6.03%
C: 2.76%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 0.33%
H: 0.52%
C: -0.47%
lumakras trial 100 cancer pancreatic
Leap Therapeutics to Present Positive New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ASCO GI Cancers Symposium
Published: 2022-01-18 (Crawled : 00:00) - biospace.com/
LPTX | $3.24 0.94% 0.93% 89K
|
Health Technology
|
| O: -4.23%
H: 0.0%
C: 0.0%
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: -2.98%
H: 0.0%
C: 0.0%
dkn-01 symposium therapeutics asco positive cancer
Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in Asia in Collaboration with BeiGene and Associated Milestone Payment
Published: 2021-12-09 (Crawled : 14:30) - biospace.com/
ZYME | $8.56 -1.72% -1.75% 340K
|
Health Technology
|
| O: -1.06%
H: 1.33%
C: -14.03%
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 1.58%
H: 1.7%
C: -4.5%
expansion trial collaboration milestone
HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer
Published: 2021-12-06 (Crawled : 01:00) - globenewswire.com
HCM | $18.2 7.44% 6.92% 120K
|
Health Technology
|
| O: -7.75%
H: 0.0%
C: 0.0%
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: -11.5%
H: 0.0%
C: 0.0%
trial cancer colorectal cancer enroll
Amgen Announces Positive Top-Line Results From Otezla® (apremilast) Phase 3 DISCREET Study In Moderate To Severe Genital Psoriasis
Published: 2021-12-01 (Crawled : 22:00) - biospace.com/
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 3.7%
H: 3.74%
C: -0.91%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 0.78%
H: 2.59%
C: 0.18%
psoriasis positive results phase 3 topline
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.